Actinium-225 Pretargeted Radioimmunotherapy against Colorectal Cancer using Self-Assembling and Disassembling Antibodies

Colorectal cancer (CRC) remains a leading cause of cancer deaths worldwide. GPA33, expressed on 95% of CRC, has been extensively targeted by IgG-attached payloads in conventional radioimmunotherapy (RIT), but toxicity was dose-limiting. A 2-step pretargeted radioimmunotherapy (PRIT) regimen using Self-Assembling-Disassembling antibody (SADA) specific for GPA33 (10 mg/kg) intravenous (IV) in step #1 and 24 h later [86Y]Y-ABD (9 nmole) IV in step #2, avoided normal gut uptake in non-human primates. Dosimetry results based on tissue counting in murine models using GPA33-SADA IV in step #1 and [225Ac]Ac-Pr in step #2, were 30.88, 0.1 and 2.56 Gy/uCi (Gy/37 kBq; RBE= 1), respectively for subcutaneous (sq) SW1222 tumor, blood and kidney, demonstrating favorable therapeutic ratios (309 for blood; 12 for kidney). Established sq SW1222 xenografts treated with 225Ac-SADA-PRIT showed dose dependent improvement in median survival (MS). Using one cycle of 2 doses 7 days apart (74kBq + 74kBq of 225Ac), majority of mice had complete tumor volumetric responses of sq SW1222, LS174T, LOVO and intraperitoneal SW1222 xenografts. Complete response was confirmed histologically at 180 days, accompanied by statistically significant improvements in MS. All treatments were well tolerated, with transient reversible weight loss (<15%), minimal hematologic, and no acute (within 30 days post 225Ac) chemical toxicities. At necropsy, kidneys showed minimal to marked subclinical tubular injury. The ability of a single cycle of 225Ac-SADA-PRIT to induce major CRC response and durable remission with minimal acute toxicities in multiple xenograft models while avoiding on-target off-tumor gut toxicity is encouraging, although subclinical histologic renal and ovarian damage remain a concern.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.18.767407
Primary Topic
Radiopharmaceutical Chemistry and Applications
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Actinium-225 Pretargeted Radioimmunotherapy against Colorectal Cancer using Self-Assembling and Disassembling Antibodies

Garrett Michael Nash, Steven M. Larson, Edward K. Fung, Sarah M. Cheal et al.
bioRxiv (Cold Spring Harbor Laboratory)
Radiopharmaceutical Chemistry and Applications
preprint

Actinium-225 Pretargeted Radioimmunotherapy against Colorectal Cancer using Self-Assembling and Disassembling Antibodies

Garrett Michael Nash, Steven M. Larson, Edward K. Fung, Sarah M. Cheal, Andrea Cercek, Nai‐Kong V. Cheung, Alexandre B. Le Roux, Michael Bonner Foote, Georgios Karagkounis, Nicole Aguirre, Jorge A. Carrasquillo, Sebastian K. Chung, Renata M. Mammone, Irene Y. Cheung, Darren R. Veach, Yong Wang, Hong Xu, Sebastian E. Carrasco, Karina Leung, Michelle Kim, Navya Vemula, Sang-Gyu Lee, Hong-Fen Guo, Yi Feng
preprint en

Abstract

Colorectal cancer (CRC) remains a leading cause of cancer deaths worldwide. GPA33, expressed on 95% of CRC, has been extensively targeted by IgG-attached payloads in conventional radioimmunotherapy (RIT), but toxicity was dose-limiting. A 2-step pretargeted radioimmunotherapy (PRIT) regimen using Self-Assembling-Disassembling antibody (SADA) specific for GPA33 (10 mg/kg) intravenous (IV) in step #1 and 24 h later [86Y]Y-ABD (9 nmole) IV in step #2, avoided normal gut uptake in non-human primates. Dosimetry results based on tissue counting in murine models using GPA33-SADA IV in step #1 and [225Ac]Ac-Pr in step #2, were 30.88, 0.1 and 2.56 Gy/uCi (Gy/37 kBq; RBE= 1), respectively for subcutaneous (sq) SW1222 tumor, blood and kidney, demonstrating favorable therapeutic ratios (309 for blood; 12 for kidney). Established sq SW1222 xenografts treated with 225Ac-SADA-PRIT showed dose dependent improvement in median survival (MS). Using one cycle of 2 doses 7 days apart (74kBq + 74kBq of 225Ac), majority of mice had complete tumor volumetric responses of sq SW1222, LS174T, LOVO and intraperitoneal SW1222 xenografts. Complete response was confirmed histologically at 180 days, accompanied by statistically significant improvements in MS. All treatments were well tolerated, with transient reversible weight loss (<15%), minimal hematologic, and no acute (within 30 days post 225Ac) chemical toxicities. At necropsy, kidneys showed minimal to marked subclinical tubular injury. The ability of a single cycle of 225Ac-SADA-PRIT to induce major CRC response and durable remission with minimal acute toxicities in multiple xenograft models while avoiding on-target off-tumor gut toxicity is encouraging, although subclinical histologic renal and ovarian damage remain a concern.

bioRxiv (Cold Spring Harbor Laboratory)
Memorial Sloan Kettering Cancer Center (US), Weill Cornell Medicine (US)
Radiopharmaceutical Chemistry and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon